Hostname: page-component-7bb8b95d7b-5mhkq Total loading time: 0 Render date: 2024-09-20T10:22:37.696Z Has data issue: false hasContentIssue false

Nalmefene for daily consumption of alcohol

Published online by Cambridge University Press:  23 March 2020

J. Valdés Valdazo*
Affiliation:
Leon, SpainLeon, Spain
L.T. Velilla Diaz
Affiliation:
Caule, Psychiatry, Leon, Spain
C. Martínez Martínez
Affiliation:
Caule, Psychiatry, Leon, Spain
A. Serrano García
Affiliation:
Caule, Psychiatry, Leon, Spain
C. Manso Bazus
Affiliation:
Caule, Psychiatry, Leon, Spain
C. Llanes Álvarez
Affiliation:
Complejo Asistencial Zamora, Psychiatry, Zamora, Spain
*
* Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

The level of high-risk alcohol consumption WHO is estimated at more than 40 mg for women and 60 mg for men.

Nalmefene is a new treatment that breaks the cycle of continued use of alcohol.

Methodology

A sample of 18 patients of a Mental Health Centre in the province of Leon alcohol dependent and high consumption They received nalmefene 18 mg daily continuous treatment for 6–9 months is selected. We appreciate the adherence of patients and the efficacy, tolerability and impact on physical health.

Results

We appreciate reduction in the amount of alcohol ingested observed by both the patient and their relatives without any cases of neglect and few side effects.

We got two patients leave the alcohol completely and an average decline in consumption over 9 Basic Units of Drink.* (90 g).

We observed improvement in the quality of life in patients with multiple pathologies and difficult social situation.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
EV115
Copyright
Copyright © European Psychiatric Association 2016
Submit a response

Comments

No Comments have been published for this article.